Coverage with Evidence Development: A Road to Accelerated Biomarker Adoption
This article was originally published in RPM Report
Oncology biomarkers have the potential to significantly improve the quality and efficiency of health care, but their value hinges on whether payers will support the science. Private payer adoption of CMS' "coverage with evidence development" decisions could provide the appropriate regulatory and reimbursement framework.
You may also be interested in...
A Medicare advisory committee brought few surprises for Dendreon’s prostate cancer therapy Provenge. Will CMS provide full coverage for Provenge or will it restrict use through coverage with evidence development?